Skip to content

miR-143-3p alleviates inflammatory response and myocardial injury after myocardial infarction by inhibiting ADAM17 expression

miR-143-3p alleviates inflammatory response and myocardial injury after myocardial infarction by inhibiting ADAM17 expression

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109497
Enrollment
Unknown
Registered
2025-09-19
Start date
2025-10-01
Completion date
Unknown
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Control group:None

Sponsors

Zhengzhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: AMI group: Patients over 18 years old who visited the Emergency Department or Outpatient Department of Zhengzhou Central Hospital due to "chest pain or equivalent symptoms" and were suspected of having AMI, and who were diagnosed with AMI and received standardized treatment and coronary revascularization therapy. Control group (non-AMI group): Patients who were confirmed to have non-AMI within 3 days of hospitalization after the onset of the disease served as the control group.

Exclusion criteria

Exclusion criteria: 1. Those with hematological diseases, autoimmune diseases, and mental illnesses; 2. Combined with cerebrovascular disease; 3. Patients with liver and kidney dysfunction; 4. Patients with malignant tumors; 5. Combined with serious infectious diseases; 6. Combined with arrhythmia, chronic heart failure, congenital heart disease, cardiomyopathy, history of myocardial infarction, or previous atrial fibrillation.

Design outcomes

Primary

MeasureTime frame
Major adverse cardiovascular events;RT-PCR was used to detect the expression levels of miR-143-3p in the AMI group and the control group;

Countries

China

Contacts

Public ContactYang Dongwei

Zhengzhou Central Hospital

yangdongwei@126.com+86 150 3829 2676

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026